Johnson & Johnson (NYSE: JNJ) Earnings Preview: What to Expect from the Pharmaceutical Giant

• Johnson & Johnson (NYSE: JNJ) is set to release its Q3 2026 earnings report on October 13, with analysts forecasting earnings per share of $2.66 and revenue of $25.40 billion.
• Despite a projected 5% year-over-year decline in EPS, the company's revenue is expected to grow by 5.8%, building on a consistent track record of beating earnings estimates.
• Key financial ratios highlight Johnson & Johnson's stock valuation and financial health, including a trailing price-to-earnings ratio of 29.65, a price-to-sales ratio of 6.31, and a debt-to-equity ratio of 0.58.

Johnson & Johnson (NYSE: JNJ), a leading global pharmaceuticals and medical devices company, reports its latest earnings report before the market opens on October 13, 2026. Wall Street analysts are closely watching, with expectations for earnings per share of $2.66 and revenue of approximately $25.40 billion for the quarter.

Analysts expect earnings per share for Johnson & Johnson to fall 5% from a year earlier, as highlighted by Zacks Investment Research. Their revenue forecast is $25.37 billion, representing a projected increase of 5.8%. The earnings estimate has seen a slight adjustment, falling 0.3% over the past 30 days.

Johnson & Johnson has a strong track record of exceeding earnings estimates, beating expectations in each of its past two quarters with an average surprise of 1.62%, according to Zacks Investment Research. In the most recent quarter, the company reported $2.90 per share against an estimate of $2.84. The quarter prior saw earnings of $2.70 per share compared to an estimate of $2.67.

Examining Johnson & Johnson's stock valuation, its trailing price-to-earnings ratio stands at 29.65, indicating its share price is 29.65 times its earnings over the past year. The company's price-to-sales ratio is 6.31, meaning its market value is 6.31 times its annual sales. Furthermore, its debt-to-equity ratio, a key measure of financial health comparing debt with shareholders’ equity, is 0.58.